Severe Neurotoxicity in Multiple Myeloma Patient Treated with Elranatamab
Author Information
Author(s): Muacevic Alexander, Adler John R, Kikuchi Taku, Kunisada Kodai, Sato Kota, Tsukada Nobuhiro, Ishida Tadao
Primary Institution: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, JPN
Hypothesis
What are the risk factors for severe immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated with elranatamab?
Conclusion
This case highlights the potential for severe neurotoxicity in patients treated with elranatamab, even in those without current neurological deficits.
Supporting Evidence
- This is the first reported case of grade 4 ICANS in a patient treated with elranatamab.
- The patient had a history of cerebral hemorrhage but no current neurological deficits.
- High-dose methylprednisolone therapy was required to manage the severe neurotoxicity.
Takeaway
One patient with multiple myeloma experienced severe side effects from a new drug called elranatamab, showing that even people who seem healthy can have serious reactions.
Methodology
Case report detailing the clinical course and treatment of a patient with multiple myeloma who developed severe ICANS after elranatamab administration.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's experience.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
60-year-old woman with a history of multiple myeloma and cerebral hemorrhage.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website